Comparative Pharmacology
Head-to-head clinical analysis: CIMERLI versus MACUGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIMERLI versus MACUGEN.
CIMERLI vs MACUGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIMERLI (ranibizumab-eqrn) is a vascular endothelial growth factor (VEGF) inhibitor. It binds to VEGF-A isoforms (e.g., VEGF110, VEGF121, VEGF165) and prevents their interaction with receptors VEGFR-1 and VEGFR-2 on endothelial cells, thereby inhibiting angiogenesis and reducing vascular permeability.
Pegaptanib is a pegylated modified oligonucleotide that binds to and inhibits vascular endothelial growth factor (VEGF-165), reducing angiogenesis and vascular permeability.
0.5 mg (0.05 mL) administered by intravitreal injection once monthly (approximately every 28 days).
Intravitreal injection of 0.3 mg (0.09 mL) once every 6 weeks.
None Documented
None Documented
Terminal elimination half-life: 5.9 days (range 4.0–7.5 days) in patients with neovascular AMD after intravitreal administration. This supports monthly or bimonthly dosing intervals.
The terminal elimination half-life in plasma is approximately 10 days following intravitreal administration, consistent with slow clearance from the vitreous cavity and systemic absorption.
Primarily eliminated via intracellular catabolism; urinary excretion of intact drug is negligible (<0.1%). Biliary/fecal excretion of intact drug is minimal. No renal or hepatic metabolism in the classical sense.
Pegaptanib is eliminated primarily via renal excretion, with the parent compound and metabolites excreted in urine accounting for >90% of the administered dose. Biliary/fecal elimination is negligible (<5%).
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor